GOLD NANOPARTICLES OR COLLOIDAL GOLD MAY SIGNIFICANTLY BOOST HUMAN IQ (20%) OR PROVIDE LONG-TERM COGNITIVE ENHANCEMENTS: A Critical Analysis of Historical Claims and Modern Nanobiological Evidence

I. Executive Summary: Scientific Skepticism and the Efficacy Gap

The assertion that colloidal metallic gold may induce a significant cognitive boost, such as a 20% increase in human Intelligence Quotient (IQ), traces its provenance almost entirely to a singular, foundational pilot study published in 1998.[1] This expert report investigates this specific claim by rigorously contrasting the findings of that early work with the robust body of contemporary scientific literature concerning gold nanoparticles (AuNPs), nanobiokinetics, neuropharmacology, and toxicology.

The analysis establishes a critical boundary between the historical, largely unsupported consumer claim regarding simple colloidal gold and the legitimate, ongoing academic and therapeutic research involving highly engineered gold nanoparticles utilized for advanced applications in neurodegenerative disease treatment.

The investigation concludes that the foundational 20% IQ increase claim is scientifically unsound. This conclusion is predicated on two fundamental analytical failures within the original study: insurmountable methodological limitations, including an extremely small participant cohort (N=5) and overwhelming potential for practice effect bias.[2] Furthermore, modern, sophisticated nanobiokinetics data demonstrate severe pharmacological bottlenecks for orally administered gold, particularly **extremely low systemic bioavailability** and **minimal translocation across the Blood-Brain Barrier (BBB)**.[3]

While advanced AuNP research shows promise for *neuroprotective* applications—mitigating pathology such as oxidative stress and amyloid aggregation *in vitro* [5]—these materials have failed to demonstrate cognitive *enhancement* in recent chronic oral administration animal

models. Indeed, some chronic exposure studies indicate undesirable behavioral shifts, such as increased anxiety levels.[4] Therefore, the current scientific evidence does not support the use of colloidal gold as a reliable or proven nootropic agent capable of providing long-term cognitive enhancements in healthy individuals.

II. Critical Review of the Genesis of the Claim (Abraham, McReynolds, & Dill, 1998)

II.I. Methodology and Context of the Pilot Study

The claim that colloidal gold substantially boosts human intelligence originates from the pilot study, "Effect of colloidal metallic gold on cognitive functions," conducted by Abraham, McReynolds, and Dill in 1998.[1] The methodological structure of this study provides the immediate basis for challenging its sensationalized conclusions. The trial involved a critically small cohort, comprising only **5 subjects** ranging in age from 15 to 45 years (4 females, 1 male).[2] The intervention involved administering colloidal metallic gold (specifically Aurasol®) at a daily dosage of 30 mg over a period of 4 weeks.[1]

The study's commercial context also warrants scrutiny; it was conducted by Optimox Corporation, suggesting a significant risk of commercial bias influencing interpretation and dissemination of the results.[2] Cognitive assessment was performed using the revised Wechsler Intelligence Scale (WAIS-R), a widely accepted battery of tests. Crucially, the WAIS-R was administered three times: a baseline test, a test post-intervention (after 4 weeks on colloidal gold), and a final follow-up test 1 to 3 months after discontinuing the gold preparation.[2]

II.II. Quantitative Results Analysis: The 20% IQ Increase

The reported quantitative findings are the central component of the enduring public interest. After the 4-week intervention period, the authors reported a statistically significant **20% increase in the WAIS-R total scores (I.Q)**.[1] Quantitatively, the mean $\pm$ SE pre-gold I.Q. score was 112.8 ± 2.3, which rose dramatically to 137 ± 3.8 post-gold administration, yielding a high statistical significance ($p < 0.005$).[2] This increase of approximately 24 full-scale IQ points is biologically extraordinary for a four-week period induced by a supplement. The authors further specified that both the **performance test scores** and the **verbal test scores** contributed equally to this purported IQ increase.[2]

The methodological limitations inherent in the study design render this statistical finding questionable, regardless of the reported p-value. A statistical significance of $p < 0.005$ in a population size of only $N=5$ is almost always indicative of a statistical artifact rather than a robust, reproducible biological truth. The fundamental problem lies in the absence of a control or placebo group combined with the **practice effect**. The WAIS-R, particularly the timed performance subtests, are susceptible to score inflation upon repeated administration

as subjects become familiar with the procedures and timing constraints.

The authors claimed the equal contribution from the non-learning verbal scores suggests the effect was genuine and not solely attributable to learning from repetition.[2] However, in a sample size so small, performance improvements are highly susceptible to individual, idiosyncratic factors. The magnitude of the effect (20%) is inconsistent with any known short-term intervention affecting healthy, non-deficient cognition, leading to the conclusion that the reported cognitive boost is scientifically untenable due to overwhelming confounding variables and insufficient statistical power.

II.III. Durability of Effect and Carry-over Claims

The study also attempted to gauge the duration of the effect. The total IQ scores were reportedly **persisted in 3 subjects** who were tested 1 to 2 months after stopping the gold preparation.[2] This was used to suggest a lasting influence beyond the clearance of the substance.

However, the lack of a uniform follow-up testing schedule (some subjects tested at 1 month, others at 2 months, others at 3 months) prevents a conclusive analysis of the decay or persistence of the effect. Crucially, in the **2 subjects** who were tested **3 months after stopping** the colloidal gold, their IQ scores had **reverted to baseline levels**.[2] This ultimate return to baseline, despite the expectation that systemically absorbed AuNPs should exhibit slow systemic clearance, strongly suggests that any transient improvement observed was not sustained, thereby invalidating any claim of "long-term cognitive enhancements" resulting from the intervention.

Table 1: Critical Appraisal of Abraham et al. (1998) Pilot Study Results

Metric	**Pre-Gold Mean (WAIS-R)**	**Post-Gold Mean (WAIS-R)**	**Reported Change (%)**	**Critical Assessment of Validity**
Full Scale IQ (N=5)	112.8 ± 2.3	137 ± 3.8	+20%	Insufficient statistical power ($N=5$); highly susceptible to learning/practice effects and commercial bias.

Verbal Scores	61.4 ± 2.4	75.4 ± 4.5	+22.8%	Biologically improbable short-term cognitive gain; lack of placebo control invalidates claims of non-learning improvement.
Performance Scores	51.4 ± 0.83	61.6 ± 1.9	+19.8%	Improvement most likely attributable to repeated exposure to timed tasks and procedural familiarity.

III. The Pharmacological Realities: Gold Nanoparticle Biokinetics and Bioavailability

III.I. Chemical and Physical Distinction and Design Dependence

A significant disconnect exists between the consumer-grade colloidal gold used in the 1998 study and the rigorously characterized gold nanoparticles (AuNPs) used in modern nanomedicine research. The efficacy and biological fate of AuNPs are critically dependent on their physicochemical properties, including size, shape, aggregation state, and surface chemistry.[7]

Research-grade AuNPs are often synthesized using sophisticated methods, such as seeding-growth, to achieve highly monodispersed particles with specific low ellipticity, facilitating predictable biological interactions.[8] In contrast, consumer colloidal gold is often poorly defined; while scanning electron microscopy (SEM) of citrate-stabilized gold particles reveals three-dimensional structures ranging from spherical shapes to irregular forms with triangular, hexagonal, or complex facets, this variability in morphology makes precise biokinetic prediction challenging.[9] The inherent variability and lack of specific surface coating mean that consumer products are unlikely to possess the targeted properties necessary for

neuroactivity demonstrated in advanced research.

III.II. Gastrointestinal Absorption and Oral Efficiency

The most significant pharmacological hurdle facing the premise of cognitive enhancement via orally ingested gold is the issue of **bioavailability**. For any substance to affect central nervous system (CNS) function, a therapeutically relevant concentration must first survive gastrointestinal transit, be efficiently absorbed into the systemic circulation, and then cross the BBB.

Biokinetic studies conducted in rats demonstrate that orally administered Gold Nanoparticles (Au-NP) are absorbed with **extremely low efficiency**. Based on Area Under the Curve (AUC) values, the oral absorption efficiency for Au-NP was determined to be only **1.85%** of the total administered amount.[3] This absorption rate is substantially lower than that observed for orally administered gold ions (Ionic Au), which reached an efficiency of 8.54%.[3]

This low absorption rate creates a decisive pharmacological bottleneck. For a 30 mg daily dose of colloidal gold to elicit a profound biological effect such as a 20% IQ change, the concentration reaching the brain would need to be considerable. An absorption rate hovering near 2% means that only minute quantities enter the bloodstream, and the vast majority of the dose remains within the gastrointestinal tract. This pharmacological limitation provides a verifiable mechanism by which the 1998 IQ claim is rendered biologically improbable, irrespective of any potential intrinsic neuroactivity of the gold material.

III.III. Translocation and Blood-Brain Barrier (BBB) Permeability

Even the minute amount of Au-NP that enters the systemic circulation faces the final restrictive barrier: the Blood-Brain Barrier (BBB). The BBB is a highly selective semipermeable membrane that prevents most materials, particularly large or relatively inert molecules, from entering the CNS.

Analysis of chronic oral AuNP exposure in mice confirms this barrier. Post-mortem tissue analysis revealed that the accumulation of gold in the brain was the lowest of all measured tissues, measuring only $3.8 \times 10^{-5}\% \pm 1.2 \times 10^{-5}\%$ of the total administered dose per gram of dry tissue.[4]

Furthermore, biokinetic analysis indicates that the biological fate of the absorbed gold is primarily in the **nanoparticulate form**, not the more chemically reactive ionic form.[3] The known relative inertness of AuNPs, especially when compared to highly reactive nanosilver, is cited as a reason for this low accumulation in the brain.[4] While this inertness contributes to a low acute systemic toxicity profile, it simultaneously drastically limits the ability of non-engineered particles to cross the BBB. Passive diffusion or non-targeted transport mechanisms are demonstrably insufficient to deliver a cognitively effective dose. This fact explains why advanced nanomedicine approaches require complex surface modifications,

such as Polyethylene glycol (PEG) coating, to facilitate targeted transport and adequate delivery to CNS targets.[11] The lack of such sophisticated engineering in consumer-grade colloidal gold provides a definitive structural explanation for its inability to produce the claimed cognitive effects.

Table 2: Comparative Oral Absorption and Tissue Distribution of Gold Species (Rodent Models)

Gold Species	Oral Absorption Efficiency (AUC)	Primary Systemic Form	Brain Accumulation (% of Dose/g dry tissue)	Key Distribution Organs
Gold Nanoparticles (Au-NP)	$\sim$1.85% (Extremely Low) [3]	Nanoparticulate [3]	$\sim 3.8 \times 10^{-5}\%$ (Minimal) [4]	Kidney (Trace), Liver, Lungs [10]
Gold Ions (Ionic Au)	$\sim$8.54% (Moderate) [3]	Ionic [3]	Not quantified (Rapidly Distributed)	Kidney, Liver, Lung, Spleen (High Levels) [10]

IV. Mechanistic Neuroprotection: Preclinical Promise and Therapeutic Targeting

Despite the severe bioavailability issues associated with oral administration, research into engineered AuNPs has revealed several powerful neurobiological mechanisms, positioning them as highly promising therapeutic candidates—not for enhancing baseline cognition, but for mitigating neurodegenerative pathologies.

IV.I. Anti-Inflammatory and Antioxidant Mechanisms

A key mechanism identified in AuNP research is their potential to act as potent modulators of oxidative stress and inflammation, two hallmark factors in the progression of many neurological disorders.[13] Studies have shown that AuNPs can reduce oxidative stress in the brain, potentially slowing disease progression and improving patient outcomes.[13]

In a systemic context, AuNP bioconjugates have demonstrated anti-inflammatory effects *in vivo* by suppressing leukocyte adhesion to postcapillary vessel walls, an early stage of the inflammatory process.[14] Furthermore, *in vitro* studies show AuNP bioconjugates abrogating oxidative burst activation and chemotaxis in neutrophils, confirming a direct intracellular

action on the inflammatory process.[14] While traditional gold salts are recognized for their systemic anti-inflammatory properties (e.g., in treating rheumatoid arthritis), evidence is lacking to support the claim that simple colloidal gold confers these same specific anti-inflammatory or cognitive benefits.[15]

IV.II. Mitochondrial Stabilization and Cellular Homeostasis

Mitochondrial dysfunction is a recognized common feature in numerous neurological disorders. Research indicates that AuNPs may offer crucial protective effects on these organelles, preserving mitochondrial function and actively blocking the release of damaging reactive species.[5] This maintenance of mitochondrial integrity is fundamental to overall cellular homeostasis and is a vital target in combating age-related cognitive decline and disease pathology.

AuNPs also engage with cellular structures by potentially interacting with cell membranes, which may influence membrane fluidity and stability.[5] This interaction can subsequently impact crucial intracellular signaling pathways, contributing to overall protective responses within neuronal cells.[5]

IV.III. Modulation of Protein Misfolding (Anti-Amyloid Activity)

One of the most compelling therapeutic applications of AuNPs is their capacity to interfere with the aggregation of misfolded proteins. Specific studies demonstrate that AuNPs may impede the pathogenic aggregation of key proteins, such as Amyloid-beta (Aβ) in Alzheimer's Disease (AD) and alpha-synuclein (α-synuclein) in Parkinson's Disease (PD).[5]

The efficacy of this neuroprotection against Aβ-induced cytotoxicity is highly dependent on the particle’s surface chemistry and structure. For instance, studies examining chirality show that d-penicillamine-coated AuNPs provided stronger neuroprotection compared to the l-form, demonstrating superior efficacy in reducing oxidative damage and preserving neuronal function.[6]

The totality of robust mechanistic evidence strongly points toward AuNPs serving as highly sophisticated agents for *treating* or *slowing* pathological decline (neuroprotection, anti-aggregation, anti-inflammation). This therapeutic function necessitates the specific targeting of dysfunctional biological pathways. The research firmly supports the notion of AuNPs as disease-modifying agents, a role that should not be extrapolated or misinterpreted as evidence for generalized cognitive *enhancement* in healthy, non-diseased individuals.[15]

V. Empirical Evidence: Cognitive and Behavioral Outcomes (Post-1998)

Following the flawed 1998 pilot study, comprehensive scientific research has shifted toward defining the true neurological safety and efficacy profile of engineered AuNPs. The results from rigorous modern studies, particularly those involving chronic administration, largely undermine the claims of cognitive enhancement.

V.I. Lack of Direct Human Efficacy Replication

The scientific community has yet to produce any solid, verifiable evidence that colloidal gold offers noteworthy cognitive benefits.[15] The concept remains scientifically interesting but lacks comprehensive support, reinforcing the expert caution against regarding it as a "magic bullet" for improving mental clarity or brain function.[15]

V.II. Chronic Oral Administration Studies in Mammals (Efficacy)

To directly test the impact of chronic exposure, a critical 2023 study investigated the effects of chronic oral administration of AuNPs (during pregnancy and lactation) on the cognitive abilities of mice offspring. The study utilized the Morris Water Maze (MWM), a standard test for spatial memory and orientation.

The key finding of this investigation was the observation of **no significant differences in spatial orientation and memory** between the experimental young mice exposed to AuNPs and the control animals.[4] In other words, the chronic oral presence of AuNPs did not influence the cognitive abilities of the exposed mice.[4] This null result, derived from a modern, chronic-exposure animal model using defined nanoparticles, provides direct empirical refutation of the concept of significant cognitive enhancement stemming from oral gold administration, particularly against the backdrop of the methodologically compromised 1998 pilot study.

V.III. Unforeseen Behavioral Consequences (Emotional State)

While the chronic oral administration of AuNPs did not lead to improvements in spatial memory, the same study identified an important adverse behavioral modulation. The experimental young mice demonstrated **higher levels of anxiety** in the Elevated Plus-maze test compared to control animals.[4] This anxiety was evidenced by observable behavioral markers, including prolonged stays in the closed arms of the maze, an increase in long grooming behaviors, and decreased running activity.[4]

This finding is highly consequential for understanding the risks of chronic ingestion. Although the amount of gold penetrating the CNS is minimal (as discussed in Section III), this small dose may still be sufficient to subtly interfere with normal neurological signaling pathways responsible for regulating emotional states. The finding of heightened anxiety, in the absence of cognitive benefit, introduces an unquantified risk of psychological dysregulation or adverse emotional side effects for chronic users of colloidal gold.

Table 3: Summary of Current AuNP Neurobiological Findings (Mechanism and Efficacy)

Biological Target/Effect	Observed Outcome (Pre-clinical)	Relevance for Therapeutic Design	Efficacy for Nootropic Enhancement
Aβ and α-synuclein Aggregation	Interference/Impede Misfolding [5]	High: Potential for AD/PD drug development.	None: Targets pathological decline, not healthy function boost.
Mitochondrial Function	Preservation and Protection [5]	High: Cellular homeostasis maintenance in neurological disorders.	Low: Requires high CNS delivery; no evidence for supra-baseline function.
Spatial Memory (Mice, Chronic Oral)	No significant difference observed [4]	Low: Direct test of enhancement yields a null result.	None: Direct contradiction of enhancement claims.
Anxiety Levels (Mice, Chronic Oral)	Heightened anxiety observed [4]	High: Signals potential adverse behavioral side effects from chronic exposure.	Negative: Potential for emotional dysregulation.

VI. Toxicological Profile and Risk Assessment

A thorough assessment of colloidal gold and AuNPs requires balancing the purported benefits against established toxicological data, especially concerning long-term use.

VI.I. Acute and Short-Term Oral Toxicity Assessment

Generally, acute and short-term toxicological evaluations suggest that AuNPs, given their inert nature, exhibit low systemic toxicity. Fourteen-day repeated oral toxicity evaluations conducted in rats showed that Au-NP did not cause severe toxicity based on standard histopathological, hematological, and serum biochemical analyses.[3] Similarly, intramuscular injection of AuNPs (150 µg/kg) over 40 days in pregnant rabbits demonstrated no significant toxic effect on essential hematological parameters, including White Blood Cell (WBC) count,

Red Blood Cell (RBC) count, hemoglobin (HGB) level, and Hematocrit (HCT) percentage.[7] These results confirm the relative safety of AuNPs for short-term systemic use, supporting their potential for therapeutic and diagnostic applications via parenteral routes.[14]

VI.II. Long-Term and Chronic Exposure Concerns (Cellular Level)

While short-term systemic toxicity appears low, the potential risks associated with chronic oral administration must be evaluated, particularly in the gastrointestinal (GI) tract. Given the extremely low oral absorption rate (1.85%), the majority of the administered dose of colloidal gold resides within the GI tract for extended periods.

An *in vitro* study investigating the cytotoxicity of Au-NP on human intestinal cells revealed a critical finding: although short 24-hour exposures did not cause cytotoxicity, when a small number of cells were exposed to Au-NP for seven days (simulating localized chronic exposure), their **colony forming ability remarkably decreased**.[12] This finding suggests a potential for cumulative toxicity to the GI epithelium after prolonged exposure at high local concentrations, which is precisely the situation that arises from the chronic ingestion of a poorly absorbed substance. Therefore, the immediate and most likely consequence of chronic oral colloidal gold use may be subtle, cumulative toxicity localized to the gastrointestinal lining, challenging the common assumption that gold's inertness renders it universally benign upon chronic ingestion.

VI.III. Confounding Environmental Neurotoxicity (Arsenic)

A critical counterpoint to the idea that gold universally benefits cognitive function is the established environmental neurotoxicity often linked to gold mining activities. Research conducted in a historic gold mining area (Hutti, North Karnataka, India) demonstrated that environmental arsenic contamination is a major health risk.[17]

Arsenic, which contaminates the ground water in these mining areas at levels significantly exceeding WHO standards, is a known neurotoxin. Chronic arsenic exposure has been shown to alter cognitive function, resulting in significantly reduced IQ scores in children residing in the affected area (Hutti mean IQ 17.95 compared to 30.55 in the control group).[17] This environmental context underscores the necessity of strict purity and quality control for any ingested product derived from gold sources, as the industrial processes associated with obtaining the material can introduce contaminants that severely and demonstrably reduce cognitive function.

VII. Synthesis and Concluding Expert Judgement

VII.I. Definitive Rebuttal of the 20% IQ Claim

Based on a comprehensive review of the scientific literature, the assertion that colloidal gold or gold nanoparticles may significantly boost human IQ by 20% or provide long-term

cognitive enhancements is scientifically unfounded. The original 1998 pilot study, which serves as the sole source of this claim, is critically compromised by an insufficient sample size (N=5), the lack of a control group, and an overwhelming probability of practice effects contaminating the WAIS-R scores.

Furthermore, the fundamental pharmacological data confirms that oral administration of AuNPs is severely inefficient. Oral absorption efficiency is critically low (approximately 1.85%) [3], and the subsequent accumulation of the material in the brain is minimal ($\sim 3.8 \times 10^{-5}\%$ of the administered dose).[4] A dose failing to cross the BBB in significant quantity cannot realistically exert a profound central nervous system effect such as a 20% IQ enhancement.

VII.II. The Disconnect: Research Sophistication vs. Commercial Simplicity

The robust preclinical evidence demonstrating the potential of AuNPs is invariably linked to highly tailored, engineered systems that leverage specific surface chemistries (e.g., chirality-dependent coatings) or functionalized designs to overcome biological barriers and target specific pathologies like Aβ aggregation.[6] This sophisticated therapeutic role contrasts sharply with the simple, heterogeneous, and often ill-defined composition of consumer-grade colloidal gold. The generalized colloidal gold preparation, lacking this specialized engineering and facing severe bioavailability limitations, cannot bridge the immense gap between targeted therapeutic potential for disease mitigation and mass-market cognitive enhancement.

VII.III. Risk-Benefit Assessment for Unregulated Use

The scientific evidence currently demonstrates zero reliable cognitive benefits from the chronic oral administration of colloidal gold. Conversely, chronic exposure studies in mammalian models point to potential adverse consequences, including heightened anxiety levels [4] and possible long-term cumulative toxicity to the gastrointestinal epithelium.[12]

The risk-benefit calculation for the chronic, unregulated use of colloidal gold is therefore definitively negative. It should not be considered a safe or effective means of mental enhancement, but rather an unproven supplement with undefined chronic risks, particularly in the localized high-concentration environment of the GI tract.

VII.IV. Recommendations for Evidence-Based Cognitive Enhancement

For individuals seeking cognitive enhancement, the scientific consensus strongly recommends focusing on proven, non-pharmacological methods.[15] These strategies, supported by comprehensive research, include: maintaining a healthy and balanced diet, engaging in regular physical exercise, prioritizing good sleep hygiene, and actively participating in mental exercise and intellectual stimulation. Reliance on unvalidated supplements like colloidal gold

should be avoided in favor of these established, evidence-based approaches.

Works cited

1. USE OF GOLD IN HUMAN HEALTH AND DISEASES - Journal of Ayurveda and Holistic Medicine (JAHM), accessed October 7, 2025, https://jahm.co.in/index.php/jahm/article/download/386/367/773
2. Effect of Colloidal Metallic Gold on Cognitive Functions: A Pilot Study – koloidnestriebro.sk, accessed October 7, 2025, https://koloidnestriebro.sk/effect-of-colloidal-metallic-gold-on-cognitive-functions-a-pilot-study/?lang=en
3. Toxicity and Biokinetics of Colloidal Gold Nanoparticles - PMC, accessed October 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5312906/
4. Impact of Chronic Oral Administration of Gold Nanoparticles on ..., accessed October 7, 2025, https://www.mdpi.com/1422-0067/24/10/8962
5. Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection - PMC, accessed October 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10888679/
6. Advances in Gold Nanoparticles for the Diagnosis and Management of Alzheimer's Disease, accessed October 7, 2025, https://www.mdpi.com/1999-4923/17/9/1158
7. Influence of gold nanoparticles and domperidone ... - ResearchGate, accessed October 7, 2025, https://www.researchgate.net/profile/Sabea-Abed/publication/389602519_Influence_of_gold_nanoparticles_and_domperidone_on_some_hematological_parameters_in_pregnant_rabbits/links/67c98f1ecc055043ce6e1c74/Influence-of-gold-nanoparticles-and-domperidone-on-some-hematological-parameters-in-pregnant-rabbits.pdf
8. The effects of size and synthesis methods of gold nanoparticle-conjugated MαHIgG4 for use in an immunochromatographic strip test to detect brugian filariasis - PubMed, accessed October 7, 2025, https://pubmed.ncbi.nlm.nih.gov/23164811/
9. Measuring the Size of Colloidal Gold Nano-particles using High-Resolution Scanning Electron Microscopy - NCBI, accessed October 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK604922/
10. Toxicity and Biokinetics of Colloidal Gold Nanoparticles - PubMed, accessed October 7, 2025, https://pubmed.ncbi.nlm.nih.gov/28347039/
11. Review of Gold Nanoparticles: Synthesis, Properties, Shapes ... - MDPI, accessed October 7, 2025, https://www.mdpi.com/1999-4923/16/10/1332
12. Toxicity and Biokinetics of Colloidal Gold Nanoparticles - MDPI, accessed October 7, 2025, https://www.mdpi.com/2079-4991/5/2/835
13. Gold Nanoparticles for Neurodegenerative Disease Studies | Nanopartz™, accessed October 7, 2025, https://www.nanopartz.com/Technical-Notes/Gold-nanoparticles-neurodegenerative-disease-info.asp

14. In vivo and In vitro Toxicity and Anti-Inflammatory Properties of Gold ..., accessed October 7, 2025, https://academic.oup.com/toxsci/article/142/2/497/3064913
15. Can Colloidal Gold Boost Cognitive Function? The Truth - Torskal, accessed October 7, 2025, https://www.torskal.com/can-colloidal-gold-boost-cognitive-function-the-science-behind-the-claims/
16. Advances in Gold Nanoparticles for the Diagnosis and Management of Alzheimer's Disease, accessed October 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12473956/
17. Environmental Arsenic Contamination and Its Effect on Intelligence ..., accessed October 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5488555/